Circulating miRNA Biomarkers for Alzheimer's Disease.

Eisai Inc, Biomarkers and Personalized Medicine Core Function Unit, Eisai Product Creation Systems, Andover, Massachusetts, United States of America.
PLoS ONE (Impact Factor: 3.53). 07/2013; 8(7):e69807. DOI: 10.1371/journal.pone.0069807
Source: PubMed

ABSTRACT A minimally invasive diagnostic assay for early detection of Alzheimer's disease (AD) is required to select optimal patient groups in clinical trials, monitor disease progression and response to treatment, and to better plan patient clinical care. Blood is an attractive source for biomarkers due to minimal discomfort to the patient, encouraging greater compliance in clinical trials and frequent testing. MiRNAs belong to the class of non-coding regulatory RNA molecules of ∼22 nt length and are now recognized to regulate ∼60% of all known genes through post-transcriptional gene silencing (RNAi). They have potential as useful biomarkers for clinical use because of their stability and ease of detection in many tissues, especially blood. Circulating profiles of miRNAs have been shown to discriminate different tumor types, indicate staging and progression of the disease and to be useful as prognostic markers. Recently their role in neurodegenerative diseases, both as diagnostic biomarkers as well as explaining basic disease etiology has come into focus. Here we report the discovery and validation of a unique circulating 7-miRNA signature (hsa-let-7d-5p, hsa-let-7g-5p, hsa-miR-15b-5p, hsa-miR-142-3p, hsa-miR-191-5p, hsa-miR-301a-3p and hsa-miR-545-3p) in plasma, which could distinguish AD patients from normal controls (NC) with >95% accuracy (AUC of 0.953). There was a >2 fold difference for all signature miRNAs between the AD and NC samples, with p-values<0.05. Pathway analysis, taking into account enriched target mRNAs for these signature miRNAs was also carried out, suggesting that the disturbance of multiple enzymatic pathways including lipid metabolism could play a role in AD etiology.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Circulating microRNAs (miRNAs) hold great promise as easily accessible biomarkers for diverse (patho)physiological processes, including aging. We have compared miRNA expression profiles in cell-free blood from older versus young breast cancer patients, in order to identify "aging miRNAs" that can be used in the future to monitor the impact of chemotherapy on the patient's biological age. First, we assessed 175 miRNAs that may possibly be present in serum/plasma in an exploratory screening in 10 young and 10 older patients. The top-15 ranking miRNAs showing differential expression between young and older subjects were further investigated in an independent cohort consisting of another 10 young and 20 older subjects. Plasma levels of miR-20a-3p, miR-30b-5p, miR106b, miR191 and miR-301a were confirmed to show significant age-related decreases (all p≤0.004). The remaining miRNAs included in the validation study (miR-21, miR-210, miR-320b, miR-378, miR-423-5p, let-7d, miR-140-5p, miR-200c, miR-374a, miR376a) all showed similar trends as observed in the exploratory screening but these differences did not reach statistical significance. Interestingly, the age-associated miRNAs did not show differential expression between fit/healthy and non-fit/frail subjects within the older breast cancer cohort of the validation study and thus merit further investigation as true aging markers that not merely reflect frailty.
    PLoS ONE 10/2014; 9(10):e110644. · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Schizophrenia is a severe mental illness and the most common complex neuropsychiatric disorder. To date, the etiology of schizophrenia is unclear; consequently, the diagnosis of schizophrenia is controversial. Biomarkers that reflect the dysregulations observed in schizophrenia may potentially assist the diagnosis of the disorder. However, the majority of these biomarkers are found in the brain tissue, which is not readily accessible, leading to the search for novel biomarkers that are present in the peripheral blood. microRNAs (miRNAs) are small non-coding RNAs that function as post-transcriptional regulators of gene expression. Previous investigations have revealed that miRNAs may play a potential role in neurodevelopment and maturation, including neurite outgrowth, dendritogenesis and dendritic spine formation. These developments highlight the significance of miRNAs as potential diagnostic biomarkers for schizophrenia. To date, miRNA biomarkers have been predominantly extracted from the brain tissue; however, future studies should examine the use of peripheral blood miRNAs as biomarkers, as these are more accessible.
    Experimental and therapeutic medicine 12/2014; 8(6):1671-1676. · 0.94 Impact Factor
  • Source
    Frontiers in Neurology 09/2014; 5:181.

Full-text (2 Sources)

Available from
May 17, 2014